GLOBAL-RAYTUR
On May 9th , the mid-term conference of the World Ports Conference was held by International Association of Ports and Harbors (IAPH) in Baku, Azerbaijan. Over 300 ports and port-related companies and organizations worldwide participated in the Conference. As the host for World Ports Conference 2019 and an important foreign trade port of China, Guangzhou Port Authority extended its warm invitation to all guests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180510006415/en/
To host World Ports Conference 2019 is a milestone for Guangzhou Port. It is also an important step to accelerate the construction and development of national central cities and shipping hubs and the forming of a new pattern of all-around opening up in China. Ms.Yuan stated that “the development of the port cannot be separated from the city. It is even more than just cooperation with the port sector. Instead, the projects should be the trigger activating trades, logistics, ports and other departments to jointly develop and standardize the ports.” She also mentioned that during 31st World Ports Conference in Guangzhou next year the host will launch the ‘Friend Circle’ Initiative for ports along ‘Belt and Road’ to promote trade facilitation and internationalization of Chinese standards.
This time Guangzhou Port Authority chose “Collaborate Now, Create Future” as the theme in its exhibition area, where fully demonstrated the port of Guangzhou as an international shipping hub which is always dedicated to improving modern shipping logistics services and building a smart green and safe port, as well as deepening the exchanges and cooperation internationally. Guangzhou Port Authority also signed a sister port cooperation agreement with Baku International Sea Trade Port, who becomes the 42nd sister port of Guangzhou. Thanks to the conferences of IAPH, Guangzhou Port now maintains friendly cooperation with over 100 countries and 400 ports worldwide.
Since the issuance of the "Three-Year Action Plan for the Construction of the Guangzhou International Shipping Center" in 2015, three years of hard work has led to a big leap in port production, the gathering and radiation power has expanded, new breakthroughs have been made in factor gathering, and key projects such as the Nansha International Cruise Terminal have kicked off. The construction will add new momentum to the gateway hub. China (Guangzhou) International Freight single window has become a leading and demonstrative example among its peers in China.
With the launch of the new 3-year Action Plan, the port of Guangzhou will use the port as a fulcrum to strengthen the connectivity with the regions and cities along the “Belt and Road” initiative, and rapidly enhance the internationalization process of Guangzhou Port. By strictly following the “Belt and Road” initiative and grasping the opportunities of the policy of building a powerful country with strong traffic, powerful oceans, as well as the Bay Area construction of Guangdong, Hong Kong, and Macao, multiple measures will be taken together to promote the construction of the Guangzhou International Shipping Center and jointly create a world-class shipping hub.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180510006415/en/
Contact:
Global Raytur (Beijing) Public Communication Co.,Ltd
Shirley
86
13720002197
wangyishan@globalraytur.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom